Internal Selection Competitions

NEH American Rescue Plan: Humanities Organizations​ (WUSTL Key Required) Internal Selection Deadline is 04/19/2021 (OPEN); Application due to NEH 05/14/2021. 

T​he purpose of this emergency relief program is to assist institutions and organizations working in the humanities that have been adversely affected by the coronavirus pandemic. Applicants may propose new humanities projects or focus on sustaining core humanities programs and activities.

Internal Opportunities

None currently posted.

Opportunities for Current NIH Funded Researchers (Competitive Revisions & Supplements)

See examples of NIH Administrative Supplements in Box (WUSTL Key required)

*NEW* Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (Emergency Supplement – Clinical Trial Optional) (NOT-OD-21-103)

First Available Due Date: May 24, 2021; Expiration Date: May 25, 2021.

  • The National Institutes of Health (NIH) are issuing this NOSI in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This NOSI provides an expedited funding mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for RADxSM-UP is provided from the American Rescue Plan Act of 2021.
  • The NIH Office of the Director (OD) is issuing this NOSI to request competitive revision applications addressing the objectives described below. This NOSI is one of four related RADxSM-UP funding opportunities. This Testing Research Projects NOSI will support research teams with established community-engaged partnerships to address the scientific objectives described herein.

*NEW* Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-21-041)

First Available due date: April 1, 2021; Expiration Date: March 31, 2022

  • NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for continued research on the impacts of SARS-CoV-2, the coronavirus that causes COVID-19. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.
  • In order to rapidly improve our understanding of the risks, prevalence, and available control measures for SARS-CoV-2 in substance using and/or HIV-affected populations, NIDA is encouraging the submission of applications for Administrative Supplements or Competitive Revisions to active grants to address the following research areas of interest:
    • Research to determine whether substance use (especially tobacco or marijuana smoking or vaping, opioids and other drug use) is a risk factor for the onset and progression of COVID-19 as well as the prolonged health consequences of SARS-CoV-2 infection.
    • Research to understand the respiratory effects of SARS-CoV-2 infection among individuals with substance use disorders (SUD), e.g., tobacco, marijuana, opioid, and methamphetamine use disorders.
    • Research to understand how the respiratory effects of COVID-19 influence the risk for opioid overdose and outcomes related to naloxone reversal.
    • Research to develop therapeutic approaches for comorbid SARS-CoV-2 infection and SUDs.
    • Research to evaluate drug-drug interaction of medications to treat SARS-CoV-2 and substances of abuse or medications to treat SUDs.
    • Research on the causes and consequences of health disparities in the onset and progression of COVID-19 among vulnerable populations (e.g., racial/ethnic minorities, sexual gender minorities), especially those who use substances.
    • Research to identify strategies to improve and implement more equitable prevention and treatment for all populations.
    • Research to understand system-level responses to COVID-19 prevention and risk mitigation in secure settings such as prisons and jails, with a particular emphasis on detainees with substance use disorder (SUD). For example:
    • Interactions of COVID-19 treatment with SUD treatments, including medications for opioid use disorders
    • Strategies for integrating COVID-19 and other infectious disease screening, prevention, and treatment protocols with SUD treatment and other health services.
    • Research to understand system- or organizational-level responses to identify, prevent, or mitigate the impact of COVID-19 in service settings that serve vulnerable populations, including people who are homeless or unstably housed.
    • Research to understand and mitigate the impact of COVID-19 in all levels of treatment services, including methadone treatment programs and syringe exchange services.
    • Research on how potential overcrowding of emergency departments and health services impacts the treatment of opioid overdoses and opioid use disorder.
    • Research leveraging ongoing studies to assess the broad impacts of COVID-19 (e.g., school closures, food insecurity, anxiety, social isolation, family loss, economic impacts – e.g. job loss) on neurodevelopment, substance use, substance use disorders, and access to addiction treatment, with priority focus on health disparities and strategies towards equity.
    • Research on the bidirectional impacts persistent acute sequalae of COVID-19 (“long COVID”) on substance use behavior and outcomes.
    • Research on how neurological aspects of COVID-19, particularly those following acute infection, contribute to substance use disorder, interfere with the course of SUD recovery or affect toxicity of drugs of abuse.
    • Research on how addictive substances interfere with recovery from COVID-19 or contribute to post-COVID neurological symptoms.
    • Research on outreach and engagement of hard to reach population with substance use in COVID-19 vaccination programs
    • Research on how HIV among persons who use substances may impact the onset and progression of COVID-19.

Notice of Information: NHLBI Extensions for Career Development Award (K01, K08, K23, K25) Recipients Whose Career Trajectories Have Been Significantly Impacted by COVID-19 (NOT-HL-21-009)

Release date (3/16/2021); Applications due dates: 04/15/2021; 05/17/2021; 06/25/2021.

  • NIH recently released NOT-OD-21-052 which provided general guidance for early career scientists affected by COVID-19 to request no-cost extensions or funded extensions. This NHLBI Notice provides additional guidance for currently-funded NHLBI K01, K08, K23, and K25 recipients impacted by COVID-19 seeking funded extensions.

Notice of Special Interest: Impact of COVID-19 on Dementia Risk, Progression and Outcomes in ADRD Populations (NOT-NS-21-037)

First Available Due Date is May 5, 2021; Expiration Date is May 6, 2021.

  • NINDS is interested in applications for supplements to human subjects awards administered by the NINDS to conduct research on the effects of COVID-19 on the development of, or disease progression in, Alzheimer’s Disease-Related Dementias (ADRDs). ADRDs include Frontotemporal Degeneration (FTD), Lewy Body Dementia (LBD), Vascular contributions to Cognitive Impairment and Dementia (VCID), and Mixed Etiology Dementias (MED). Older adults are known to be especially vulnerable to COVID-19 infection, and COVID-19 infection commonly presents with neurological signs and symptoms. The effect of COVID-19 exposure on subjects who have, or are at risk for developing ADRDs is unclear. Investigators who are currently researching ADRD or at-risk for ADRD populations are encouraged to apply for additional support to examine the impact of COVID-19 in these subjects. Research topics of interest may include (but are not limited to):
    • The effect of symptomatic or asymptomatic COVID-19 infection on progression to cognitive impairment or dementia in populations that are at risk for ADRDs.
    • The effect of symptomatic or asymptomatic COVID-19 infection on progression of dementia in patients with existing ADRDs.
    • COVID-19 induced hyposmia/dysgeusia as a risk factor(s) for progression to dementia in at-risk for ADRD populations, or progression of dementia in people with ADRD diagnoses..
    • Evidence of new or worsening ADRD-related neurophysiology (e.g., small vessel disease, ischemia, or atrophy on MRI, alterations in blood or CSF proteins, etc.) that occur after symptomatic or asymptomatic COVID-19 infection.
  • Studies proposed in the supplement application must be within scope of the original parent application’s research. Applicants may request funds to cover the costs of additional subject enrollment, personnel, or assessments (e.g., COVID-19 testing, cognitive assessments, smell testing, neuroimaging).

Notice of Special Interest (NOSI): Administrative Supplements and Urgent Competitive Revisions for NIH Grants to Add or Expand Focused on Maternal Health, Structural Racism and Discrimination, and COVID-19 (NOT-OD-21-071)

First Available Due Date is April 14, 2021; Expiration Date is April 21, 2021.

  • The Office of the Director of the National Institutes of Health (NIH), on behalf of the NIH Maternal Mortality Task Force, announces the opportunity for investigators with relevant active NIH-supported grants to address the following scientific priorities for Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE) in the context of the ongoing COVID-19 pandemic for pregnant persons and up to one year postpartum:
    • Understand the effects of SARS-CoV-2 infection and the COVID-19 pandemic on maternal mental health, well-being, functioning and quality of life
    • Identify psychosocial and behavioral health risk factors related to the COVID-19 pandemic that affect maternal mental health and functioning outcomes
    • Address the impact of structural racism and discrimination (SRD) on maternal health outcomes in the context of COVID-19
  • NIH is soliciting the submission of applications for Administrative Supplements or Urgent Competitive Revisions to active awards that include or could extend to pregnancy and COVID-19. Applications in response to this NOSI should be aligned with one or more of the areas of interest below. Example research questions are provided for each area of interest (see announcement for the example research questions are the areas listed below):
    • Area 1: Investigate the impact of the COVID-19 pandemic on the health, well-being, and functioning of pregnant persons and up to one year postpartum using psychosocial and behavioral research approaches.
    • Area 2: Investigate the impact of SRD in the context of the COVID-19 pandemic on the health and well-being of persons during pregnancy and up to one year postpartum.
    • Area 3: Understand how knowledge, attitudes, and beliefs about COVID-19 influence decisions and behaviors related to COVID-19 testing and vaccination during pregnancy and up to one year postpartum.
    • Area 4: Develop an integrated understanding of pregnancy-related and pregnancy-associated morbidity and MM causes, related to COVID-19.

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-21-019)

First Available Due Date: March 15, 2021; Expiration Date: December 16, 2021

  • There is an urgent public health need to better understand SARS-CoV-2, particularly to improve the predictive quality of existing models of spread, diagnostics for measurement of transmission, susceptibility and recovery, efficacy and economic impact of mitigations and vaccination strategies, and differences in transmission and natural history among different SARS-CoV-2 variant strains.
  • NIGMS will accept the submission of applications for Competitive Revisions to all active NIGMS grants to address only the following research area:
    • Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive computational models for the spread of SARS-CoV-2 and other related infectious agents. Efforts may include, for example, models for vaccination or other mitigation strategies, potential economic impacts and other topics related to transmission of SARS-CoV-2 variants.

Reminder – Requesting Extensions for Early Career Scientists Whose Career Trajectories Have been Significantly Impacted by COVID-19 (NOT-OD-21-052)

Release Date: February 2, 2021

  • The COVID-19 pandemic, along with extensive mitigation measures, has adversely affected progress in many biomedical research settings. Evidence from multiple sources, including a survey NIH issued to its extramural research workforce, indicates legitimate concerns about career trajectory for early career scientists. Therefore, within existing constraints of available funding, NIH plans to support early career scientists whose career trajectories have been significantly affected by the pandemic.
  • Therefore, NIH is providing an opportunity for recipients of NIH Fellowship (“F”) and NIH Career Development (“K”) awards who have been impacted by COVID-19 to request extensions as follows:
  • No-Cost ExtensionsFor most NIH awards, recipients may extend the final budget period of the previously approved project period (e.g. no-cost extension) one time, without NIH prior approval. For Fellowships and some career development awards (e.g., K99), the first no-cost extension may be submitted by the Authorized Organization Official (AOR) as a prior approval request to the funding IC(s). Recipients may also submit prior approval requests for second no-cost extensions. These requests must include a justification outlining the impact of COVID-19 on the recipient’s training and career development activities and will be considered by the funding IC(s) on a case by case basis.

Notice of Special Interest: Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs (NOT-TR-21-017)

First Available Due Date is January 28, 2021; Expiration Date is August 17, 2024

  • The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts.
  • NCATS expects to issue 1-4 awards for involvement with clinical studies and trials in support of COVID interventions, as well as providing clinical samples and assessing infectious or convalescent status.

Notice of Special Interest: Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control (NOT-CA-21-033)

  • This Notice of Special Interest (NOSI) informs current awardees that the National Cancer Institute (NCI) is providing the opportunity for supplemental funding to stimulate interest and promote studies on the impact of the COVID-19 pandemic on global cancer prevention and control. This Administrative Supplement is designed to support NCI-funded investigators who have existing relationships/partnerships in low- and middle-income countries (LMICs), inclusive of upper-middle-income countries, to leverage those partnerships to conduct research on the pandemic’s impact on cancer prevention, diagnosis, treatment, and outcomes.
  • Studies should contribute to understanding the impact of COVID-19 on global cancer prevention and control. This may include the direct effects of COVID-19 in cancer patients or the indirect health, economic, and sociocultural impacts of the pandemic across the cancer continuum.
  • Studies that generate an evidence base necessary to mitigate the effects of this and future pandemics on persons with cancer, at risk for cancer, undergoing treatment for cancer, or in remission are especially encouraged.

Notice of Special Interest: Administrative Supplements for COVID-19 Impacted NIMH Research

Expiration Date: June 2, 2023

  • The purpose of this Notice is to outline priorities for providing supplemental funding to investigators and institutions with active National Institute of Mental Health (NIMH) awards that have been significantly impacted by the COVID-19 pandemic.
  • In concert with the NIH priorities, the NIMH aims to prioritize supplement requests in the following order:
  • Trainees with F32, K01, K08, and K23 awards that are in the last year of the award
    • Projects where the entire investment is at-risk including
    • Human subjects studies in which completion of enrollment and follow-up are critical for project success
    • Longitudinal cohort studies
    • Principal investigators whose grants are ending with no additional funding
    • Projects where substantial components of the investment are at risk
    • Resources that support multiple projects/institutions

Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) (PAR-20-256)

  • The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.
  • Applications accepted on a rolling basis.
  • NIAID intends to commit up to $25M for this initiative. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities (NOT-MD-20-025)
Expiration date is 5/8/2023; First available due date is 10/05/2020

  • Research Objectives:
    • Foster trans-disciplinary partnerships and collaborations in understanding the etiology and causal pathways of health disparities using SMSS
    • Use SMSS to identify modifiable barriers and cost-effective factors to reduce and eventually eliminate health disparities
    • Use SMSS to improve patient safety and reduce medical errors for populations affected by health disparities
    • Use SMSS to assess and predict the spread and consequences of pandemics (e.g., SARS-CoV-2) and the effectiveness of interventions in populations affected by health disparities
    • Provide evidence-based simulation or prediction of the impact of effective or ineffective health disparities interventions delivered in real-world settings
    • Promote big data harmonization and novel analytic methods in SMSS to address minority health and health disparities
  • Research Methodology
    • Examples of research methods could include but are not limited to:
    • System dynamics modeling
    • Network Analysis
    • Agent-based modeling
    • Dynamic microsimulation modeling
    • Discrete event simulation
    • Markov modeling
    • Hybrid simulation modeling (e.g., sequential design, enrichment design, integration design, and parallel design)
  • Research Topics: Applications should be relevant to the objectives of the funding opportunity announcement and to at least one of the participating institutes’ and offices’ research interests. Researchers are strongly encouraged to review the general research interests of the participating ICs.

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-059)
Notice expires on 7/2/21

  • NIAID is allowing the submission of applications for Competitive Revisions to active grants to increase and enhance select research efforts to facilitate the Federal SARS-CoV-2/COVID-19 research response. Areas of interest are limited to:
    • Support to BSL3 facilities actively engaged in the SARS-CoV-2/COVID-19 research response, e.g., equipment sharing arrangements. Applications proposing new construction, alterations and renovations for planned and active BSL3 facilities are not responsive to this NOSI;
    • Generation of critical reagents to support the SARS-CoV-2/COVID-19 research response;
    • Expansion of relevant data systems to expeditiously share SARS-CoV-2/COVID-19 research resources with the broad research community; and
    • Expansion of clinical trial infrastructure, or site preparation, for urgent SARS-CoV-2/COVID-19 clinical trial activities. Applications proposing clinical trials are not responsive to this NOSI.

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project
Application Due Dates are 11/12/20, 3/12/21, or 7/12/21

  • This NOSI highlights the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals with Down syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus.

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System
(NOT-NS-20-051)

Expires 4/15/21

  • NINDS is encouraging the submission of competitive revision or administrative supplement applications for supplements to address the biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronavirus that are directly related to the NINDS mission.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences (NOT-OD-20-097)
Applications will be accepted on a rolling basis through 3/31/21

  • OBSSR, NHLBI, NIA, NIAAA, NIDDK, NIEHS, NCCIH, NCI, and ORWH encourage submission of applications for urgent competitive revisions or administrative supplements to active grants studying existing longitudinal cohorts, particularly those cohorts with considerable data relevant to COVID-19 social and behavioral factors prior and subsequent to the SAR-CoV-2 outbreak in various locations. Submissions are encouraged to consider four areas: public health mitigation efforts; economic, social and personnel well-being; misinformation being communicated; downstream health effects from economic and social impacts.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus (NOT-MH-20-047)
Applications accepted on a rolling basis until 4/15/21

  • NIMH, NIA, NIAAA, and NIMHD are accepting applications for supplements and revisions to active projects that significantly improve our understanding of the risks, mechanisms, and treatment in response to COVID-19 among individuals at risk for, or experiencing mental disorders across the full lifespan. This includes but is not limited to, individuals with Mild Cognitive Impairment (MCI), Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD) and their healthcare providers and caregivers.

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities (NOT-MD-20-019)
Applications accepted on a rolling basis until 5/1/21

  • NIMH, NIA, and NIMHD are accepting applications for supplements and revisions to active projects. This NOSI is soliciting research in health disparity populations that -seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations.

Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) (NOT-ES-20-015 / PA-20-135)
Applications are accepted the first week of each month. See Notice for specific dates. (Notice expires on 5/4/21)

  • NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. NIEHS is accepting applications addressing COVID-19 through the urgent competitive revision, and time-sensitive mechanisms (see Application Information below).

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-AG-20-022)
Applications will be accepted on a rolling basis from April 6, 2020 through May 1, 2021

  • In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address multiple areas of interest within the mission of NIA.

NIDA Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-20-047)
Applications will be accepted on a rolling basis through 3/31/21

  • NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications must be submitted using the following funding opportunities: PA-18-935, which is intended to provide funds for NIH grantees applying to expand the scope of their active grant, or PA-18-591, which is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.

NIAID Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-031)
Application due dates depend on grant mechanism (Notice expires on 4/5/21)

  • National Institute of Allergy and Infectious Diseases (NIAID) is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. Applications may be submitted as administrative supplements (PA-18-591) to existing awards.

Clinical and Translational Science Awards Limited Funding Opportunities

Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need
Application due dates depend on grant mechanisms

NIH Funding Opportunities (New Applications)

*NEW* Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (U24 Clinical Trial Not Allowed) (RFA-AG-21-035)

Application due date is June 9, 2021.

  • The purpose of this Cooperative Resource-Related Research Project FOA is to establish a coordinating center to support and develop research, dissemination, and various data sharing activities for social, behavioral, and economic research on COVID-19. The Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (SBECCC) will foster innovation, collaboration, and synergies across researchers funded through the Social, Behavioral and Economic Research on COVID-19 Consortium (U01) program and other relevant NIH-funded studies by supporting networking activities intended to advance research in the field; supporting the development and use of harmonized COVID-19 data constructs for primary and secondary data to support comparability and replicability; assisting in efficient and enhanced sharing/discoverability of data; and disseminating findings to the research community and the public.

*NEW* Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (U01 Clinical Trial Optional) (RFA-OD-21-008)

Application due date: July 7, 2021

  • The National Institutes of Health (NIH) are issuing this funding FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This FOA provides an expedited funding mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for this program is provided from the American Rescue Plan Act of 2021.

*NEW* Emergency Award: RADx-UP – Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional) (RFA-OD-21-009)

Application due date: July 7, 2021

  • This funding opportunity announcement (FOA) uses an emergency U01 mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for this initiative is provided from the American Rescue Plan Act of 2021 .

Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium  (PAR-21-213)

Letter of Intent due dates: May 9, 2021; October 8, 2021; Expiration Date is November 9, 2021

  • The purpose of this FOA is to advance research on the impact of COVID-19 and associated mitigation efforts on individual, family, and community behavior, as well as research on how subsequent economic disruption affects health-related outcomes. Emphasis should be placed on addressing these questions in underserved and vulnerable populations (see Definitions above). Health effects/outcomes studied are not limited to direct effects of infection and can/should consider indirect and secondary effects of the pandemic. Priority research questions include but are not limited to the following:
  • Behavioral and social factors contributing to SARS-CoV-2 transmission and prevention, such as individual, family, community, and environmental influences that shape adherence to and transmission reduction from coronavirus mitigation behaviors including COVID-19 vaccination.
  • The integration of economic feedback to mitigation policies and behaviors affecting estimates of transmission/prevention. The impact of timing and design of state and local government mitigation policies on differentially affected transmission.
  • How communication disorders or use of hearing aids, American Sign Language, or associative and augmentative communication (AAC) devices impact the likelihood of contracting the SARS-COVID-2, suffering adverse effects from infections, or management of mitigation protocols.
  • Leveraging and integrating data from large cohort studies for the development of machine learning algorithms and other novel methods for prediction models of COVID-19 transmission as well as impact of interventions on transmission.
  • The impact of public health interventions to mitigate COVID-19 transmission on preventive care delivery and use (e.g., mental health care, drug/alcohol use treatment, well-visits, vaccinations, other routine preventive care) and the quantified effects on health.
  • The impact of the pandemic and the concomitant public health response on the management of chronic conditions and disabilities (e.g., cardiovascular disease, HIV, autism, individuals with spinal cord injuries), including effects on self-management of illnesses and relevant health behaviors (e.g., diet, sleep, physical activity, medication adherence, health-monitoring).
  • How the pandemic and associated mitigation policies have affected care of patients with in-person care needs (e.g., persons with dementia) and their caregivers.
  • The impact of the pandemic and concomitant public health response on the management of pregnancy and the post-partum period, including access to healthcare, self-management of health behaviors, and the impact on maternal mortality and morbidity, and pregnancy outcomes, including the management and development of pre-term and other medically fragile infants.
  • How school closures and alternative educational approaches in response to the coronavirus pandemic have affected child development and learning in the short- and long-term, including among children with physical and psychological disabilities; and how school closures have impacted parental functioning and behavioral health (e.g., stress, substance use, etc.).
  • Shifts in modes of healthcare (e.g., telemedicine) and how these shifts are impacting health outcomes.
  • Access to telehealth as a function of health disparities and vulnerability, and the impact of differential access on mental health and substance use-related concerns.
  • The underlying mechanisms linking the pandemic and mitigation strategies with mental and behavioral disorders.
  • The effect of public health mitigation efforts on family- and community-level outcomes, including but not limited to the prevalence of interpersonal violence in families; changes in prevalence of poverty at the community/county/state level; behavioral health symptoms including but not limited to depression, anxiety, and substance use; and the interaction between these various phenomena.
  • The consequences on individual and community health of policies and programs whose primary intention may not have been to address health outcomes (e.g., economic stimulus).
  • Assessment of differential death rates because of COVID that consider biological and social determinants of health.
  • The efficacy of communication to vulnerable populations about preventative health measures (e.g., hand washing, mask wearing, physical distancing, testing, vaccines) and associated adherence outcomes: what modes of communication are most effective and why?
  • Relevant approaches may include but are not limited to:
    • Development of computational, statistical, and mathematical models for the spread and outcomes of COVID-19 and results of possible interventions, including incorporation of economic models related to health and well-being.
    • “Natural experiments” making use of time and place differences in policies, programs, economic circumstances, and other exogenous factors to identify causal factors.
    • Linking of large datasets and nationally representative surveys to assess mortality, comorbidity, and healthcare utilization differentials across sex/gender, racial/ethnic, urban/rural, and socioeconomic lines.
    • Development of statistical models to predict immediate, mid-, and long-term health and economic outcomes across individuals’ lifespan.
    • Leveraging of new data sources (e.g., sensors), data integration (especially at multiple levels of influence), and artificial intelligence and computational modeling.

Notice of Intent to Publish a Research Opportunity Announcement for RADx-UP Return to School Diagnostic Testing Approaches (NOT-OD-21-097)

Release date: March 29, 2021 (Letters of interest will be due by April 16, 2021)

  • The purpose of this Notice is to alert the community that NIH plans to publish a Research Opportunity (RO) as part of the Rapid Acceleration of Diagnostics for Underserved Populations (RADxSM-UP) initiative to solicit research on COVID-19 diagnostic testing approaches to safely return children and staff to the in-person school setting in underserved and vulnerable communities (NOT-OD-21-065).
  • This open solicitation will be an opportunity to start new cohorts or approaches to gain data related to safe return to the in-person learning environment. A letter of interest will be required to be considered for the opportunity to participate in the Research Opportunity. Guidance on the development and submission of the letter of interest is available at the following web address: https://grants.nih.gov/sites/default/files/RADx-UP-LOI.pdf.The letters of interest will be reviewed by NIH staff and specific programs will be invited to submit and compete with full proposals. The letters of interest will be due by April 16, 2021, 5 PM local time of the applicant organization.

Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children (NOT-MH-21-225)

First Available Due Date is June 5, 2021; Expiration Date is September 8, 2022

  • NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to understand the mental health impact of the Coronavirus Disease 2019 (COVID-19) pandemic on school-aged children, specifically ages 3 – 12. Particularly, we are interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children. Empirical data would aid in balancing health risks for various public health mitigation strategies affecting children in the current pandemic as well as inform how to both be prepared and respond to future public health emergencies, including pandemics and disaster scenarios.

Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE)(R01) (RFA-AI-21-023)

Application Due Date: July 30, 2021

  • The purpose of this FOA is to build upon knowledge of HIV in the U.S. and to use this knowledge to create more effective, more timely, and tailored approaches to end the HIV epidemic. Research funded under this FOA will rapidly identify priority populations and where HIV is spreading and provide data-driven evidence-based guidance for public health decision-making to support the goals of the Ending the HIV Epidemic: A Plan for America (EHE) initiative through the RESPOND pillar.
  • Health systems need to adapt to more rapidly detect transmissions, identify outbreaks, and guide tailored decision-making, particularly as the epidemiology of HIV changes due to successful public health interventions or unanticipated care disruptions such as the COVID-19 pandemic. EHE demands innovative research to understand, as close to real time as possible community, structural, and population influences on HIV transmission. Respond: EEE provides an opportunity to scale-up and focus research in highly affected communities and in persons of highest need of HIV prevention, care and treatment.
  • The HIV epidemic is expected to change as the EHE initiative is successful in reducing HIV transmissions. To continue to be successful, the EHE community will need robust data to identify and communicate with stakeholders about potential changes in vulnerable populations and to implement the most appropriate and effective interventions. Along with contributing directly to EHE-specific activities, projects funded through this FOA could help to identify hidden, obscure, and/or previously unrecognized factors that contribute to HIV transmission in communities. Accurate epidemiology that is focused on the needs of implementing partners is key to the development of more timely knowledge that will better inform interventions to improve response, link those in need to appropriate care, and slow transmission.

Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration (NOT-AG-21-016)

First Available Due Date is June 5, 2021; Expiration Date is May 8, 2023.

  • The purpose of this Notice of Special Interest (NOSI) is to inform applicants to the National Institute on Aging (NIA) of NIA’s interest in basic and clinical mechanistic research on neurological and neurocognitive sequelae originating from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and Coronavirus Disease 2019 (COVID-19) in aging and age-related neurodegeneration.
  • The specific research objectives of this NOSI are to rapidly expand the knowledge base on acute and long-term neurological and neurocognitive sequelae of COVID-19. NIA encourages investigator-initiated new and resubmission applications for research activity codes (i.e., R21, R01, R03) to address significant questions about the neurological and neurocognitive impacts of COVID-19 infection in aging and the interaction in older adults of COVID-19 with comorbid conditions, including Alzheimer’s disease (AD) and AD-related dementias (ADRD). Animal and human studies are appropriate for this NOSI. This NOSI aims to promote collaborative and integrative efforts between investigators with different perspectives and backgrounds.
  • Potential Research Areas: Research applications responsive to this NOSI will include projects investigating questions of importance to neurological and neurocognitive sequelae of SARS-CoV-2 infection in aging such as, but not limited to, the following:
    • Research on neurological and neurocognitive symptoms and sequelae of SARS-CoV-2 infection in older adults across the full range of illness severity (e.g., early alterations in sensory function, delirium, neuropsychiatric symptoms).
    • Studies in the context of aging and age-related neurodegeneration of the role of brain barriers in preventing SARS-CoV-2 from gaining access to neural tissues, and mechanisms through which SARS-CoV-2 compromises such barriers and propagates in the central nervous system (CNS);
    • Studies to elucidate mechanisms of susceptibility to SARS-CoV-2 infection in aging and age-related neurodegeneration.
    • Research on basic mechanisms underlying the neurobiology of COVID-19 pathophysiology, such as vascular changes, neuroinflammation, or acute hypoxic damage.
    • Research on genetic risk or protective factors that may alter cognitive function in older adults who have been afflicted with COVID-19.
    • Studies of COVID-19 susceptibility in people with AD/ADRD.
    • Neuropathological studies of COVID-19 and the contribution of brain tissue damage by SARS-CoV-2 to the morbidity and mortality of COVID-19 in older adults.
    • Drug discovery research and development of novel drugs, as well as repurposing and repositioning existing drugs, for preventing and treating COVID-19 in older adults, particularly drugs that are specific for COVID-19 related CNS targets and CNS mechanisms related to or driving the viral-mediated pathophysiology, and research on blood-brain-barrier penetrant drug candidates to treat potential SARS-CoV-2 reservoirs in the CNS.
    • Research to develop computational and informatics methods (e.g., machine learning or artificial intelligence) integrating emerging multi-modal data for COVID-19 diagnosis, prevention, and treatment in older adults.
    • Research to develop devices or wearables for real-time detection and monitoring of cognitive and/or other neurological sequela in post-COVID-19 older adults.
    • Studies of long-term outcomes after recovery from COVID-19 in older adults across the range of illness severity, including neurocognitive, neuropsychiatric, and focal neurological deficits.
    • Research to develop novel models for investigating concurrent aging and neurodegenerative processes in the context of SARS-CoV-2 infection.

Notice of Intent to Publish a Research Opportunity Announcement for RADx-UP Return to School Diagnostic Testing Approaches (OT2 Clinical Trial Required)

Release date: February 12, 2021

  • The purpose of this Notice is to alert the community that NIH plans to publish a Research Opportunity (RO) as part of the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative to solicit research on COVID-19 diagnostic testing approaches to safely return children and staff to the in-person school setting in underserved and vulnerable communities. The RO will consist of two phases: 1) a targeted solicitation to rapidly accelerate ongoing research already in place in the school setting; 2) an open solicitation to start new cohorts or approaches to gain data related to safe return. The targeted solicitation will be by invitation only and will include programs currently in place in the school setting; applications will be accepted through early March 2021 for FY21 funding with the goal to make awards no later than April 2021. The open solicitation is expected to be published in mid-April and we will accept applications through early May 2021 for FY21 funding. The goal is to make awards by June 2021 for planned implementation in the 2021-2022 school year.
  • Awards under this funding opportunity will be issued as Other Transaction Agreements (OT2), which are not grants, contracts or cooperative agreements. Other Transactions awards will involve active NIH program management. Furthermore, the OT funding mechanism provides NIH with the flexibility to design unique collaborations with private sector entities that may not have experience with commonly used assistance mechanisms such as grants and cooperative agreements.
  • The goal of RADx-UP is to reduce COVID-19 associated morbidity and mortality disparities for those vulnerable and underserved populations that are disproportionately affected by, have the highest infection rates of, and/or are most at risk for adverse outcomes from contracting the virus. This Notice encourages researchers to leverage existing partnerships with key stakeholders to develop and implement specific, targeted approaches for school testing strategies to safely return children and staff to in-person school environments in underserved communities.

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 RFA-AA-21-003) (R01 RFA-AA-21-002) (R21 RFA-AA-21-004)

Expiration Date is April 15, 2021.

  • R03 This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. This FOA uses the R03 mechanism, which is intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.
  • R01 This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. Applications to this RFA should be accomplished within a three year project duration.

R21 This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. This FOA uses the R21 grant mechanism, which is intended to support investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research.

Notice of Special Interest: Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19 (NOT-DA-21-017)

First Available Due Date is May 5, 2021; Expiration Date is September 8, 2024.

  • NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.
  • Research Areas:
    • The risks that smoking and/or vaping tobacco, marijuana, cocaine, and/or methamphetamine may have on acquiring the SARS-CoV2 infection in individuals with HIV.
    • The medical consequences, co-morbidity, and complications of SARS-CoV2 infection affecting cardiovascular, respiratory, renal, gastrointestinal, hematological, immunological, CNS and PNS systems in HIV individuals who smoke and/or vape tobacco, marijuana, cocaine, and/or methamphetamine.
    • Defining mechanisms by which substance use and HIV interact to increase susceptibility to severe COVID-19 affecting cardiovascular, respiratory, renal, gastrointestinal, hematological, immunological, CNS and PNS morbidity.
    • Utilization of large database- Electronic Health Records – strategies for retrospective and platform based prospective studies, cross analyses, and real-time health delivery and critical health-related decisions in emergency medicine settings.

Notice of Special Interest: Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders (NOT-DA-21-018)

First Available Due Date is May 7, 2021; Expiration Date is September 8, 2024.

  • NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.
  • This NOSI encourages, but is not limited to, research applications in the following areas:
    • Long-term neurocognitive effects of HIV/COVID-19/SUDs. Basic science studies to explore changes in neuroanatomy, neurophysiology, biochemistry, learning and behavior.
    • Clinical studies to evaluate cognitive, behavioral, neuropsychiatric, neuro-therapeutic outcomes, etc. Staging and categorizing of cognitive dysfunction. Differentiation between HAND and COVID-19 neurocognitive impairment in individuals with and without SUDs. Validation of neurocognitive scales for HAND and COVI-19 neurocognitive impairment.
    • Neurocognitive studies in individuals with HIV/COVID-19/SUDs classified by age/gender/race/socioeconomic status/drug of choice use/ART regime/HCV status/other co-morbidities/criminal justice involvement, etc.
    • Therapeutic strategies for such neurocognitive dysfunction in the context of HIV. Effectiveness of NMDA receptor antagonists, Anticholinergics, B12 supplements, Thiamine, SSRI’s, Benzodiazepines, Antipsychotics, etc., and its interactions with ART and SUDs. Cognitive Behavioral Therapy; Mindfulness; Meditation; Transcranial Magnetic Stimulation and others.

Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (NOT-DE-21-001)

First Available Due Date is June 5, 2021; Expiration Date is May 8, 2023.

  • The oral/nasal route serves as the SARS-CoV-2 point of entry into the host thus playing a pivotal role in viral spread and COVID-19 onset and progression. As such, limiting viral infectivity, replication, shedding, and load at the point of entry is crucial to containing COVID-19 progression, as well as transmission to others. This NOSI will support studies focused on the role of oral/nasal cavity and oral manifestations related to SARS-CoV-2 and/or COVID-19 within the NIDCR mission. The areas of interest include:
    • Investigation of the biological underpinnings of SARS-CoV-2 infection, transmission, and progression in the oral cavity, including the microbiota oral-gut axis and its dysbiosis; effects of ACE2 expression distribution and function at oral/nasal SARS-CoV-2 point of entry; salivary glands as a reservoir for SARS-CoV-2; oral mucosal immunity, and differential interactions of SARS-CoV-2 mutants/variants with oral/nasal cells.
    • Investigation of the physiological mechanisms of oral manifestations of COVID-19, including salivary gland dysfunction in SARS-CoV-2 susceptibility; SARS-CoV-2 related causes of taste dysfunction; oral lesions; and changes in vascularization.
    • Establishment of predictive value and prognostic potential of oral manifestations of the severity of COVID-19 and post-acute sequalae of COVID-19.
    • Definition of the interactions between SARS-CoV-2 and oral/nasal microbiota and potential therapeutic roles of pre/probiotics and other exogenous modulators of these viral-bacterial interactions, as well as blockers of viral-receptor interactions that may limit infectivity of SARS-CoV-2.
    • Development of tools and technologies to facilitate studies in the focus areas of this initiative, including animal models, ex vivo models including oral/nasal tissue chip platforms, and computational modeling of virus-receptor interactions, among others.
  • Projects that overlap with or will result in incremental knowledge gained from existing investments in COVID-19 research by NIDCR or NIH initiatives such as the Rapid Acceleration of Diagnostics (RADx), are discouraged. Clinical observations and other descriptive studies without mechanistic analyses will be considered non-responsive.
  • Potential applicants are strongly encouraged to contact the Program Official to discuss responsiveness and appropriate mechanism before submission.

Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Conronavirus Disease 2019 (COVID-19) (NOT-AG-21-015)

First Available Due Date is March 4, 2021; Expiration Date is May 8, 2023.

  • NIA is issuing this Notice of Special Interest (NOSI) to highlight the continuing need for behavioral, psychological, social, and economic research on SARS-CoV-2 and coronavirus disease 2019 (COVID-19). There is a need for ongoing research on the longer-term effects of COVID-19 on the health and well-being of those infected, those caring for the sick, and many others whose lives were disrupted by the pandemic and its associated mitigation and prevention strategies. Beyond effects on individuals, this pandemic has brought about unprecedented social and economic disruption that is expected to have long-term and profound effects on the health of the population. These effects will likely be particularly acute for NIH-designated health disparity populations, and other COVID-19 vulnerable groups including older adults, who have experienced higher rates of COVID-19 infection, who in some cases rely on the efforts of paid and unpaid care partners, and who may have additional barriers to accessing the medical system itself. Further, middle-aged and older frontline healthcare and essential workers and their families face unique risks of exposure to both infection and other health-related outcomes by virtue of their employment.
  • Recommended areas of research include, but are not limited to, the following:
    • Use of longitudinal studies collecting multidisciplinary data (often from nationally representative and diverse samples) in order to elucidate how COVID-19 related changes in the social, economic, institutional, and policy environments differentially impact the health and welfare of people across the life course and in vulnerable social groups; inform programs and policies to prepare the world for the next pandemic; and compare regional and national impacts and approaches.
    • Use of longitudinal studies to gather unique “real-time” data for rapid assessments of risk factors and outcomes in order to guide evolving public health and treatment strategies.
    • Studies exploiting “natural experiments” associated with COVID-19 economic and health shocks as well as differences in local policies related to mitigation and prevention in order to assess direct and indirect impacts on health and well-being.
    • Studies focused on the challenges involved in informing vulnerable populations about preventative health measures (e.g., hand washing, mask wearing, physical distancing, vaccine uptake) and securing and maintaining broad adherence in order to slow virus spread and limit illness and deaths. For example: How do vulnerable groups and older adults more generally get their information and what sources do they trust? What factors support or discourage adherence to prevention practices and vaccine uptake? What accounts for individual, age, and group differences in adherence to prevention efforts? Do social networks serve to reinforce or disrupt prevention efforts?
    • Studies focused on how the short- and longer-term pandemic has influenced economic and social shocks (e.g. unemployment, foreclosure, loss of health insurance) affecting the health and well-being of different populations (e.g., rural/urban, older/middle age/younger, racial/ethnic groups).
    • Studies examining how physical distancing requirements and associated social isolation and loneliness impact the health and well-being of midlife and older adult populations, including impacts on psychological well-being, cognitive health, and health behaviors. What strategies implemented by individuals, health systems, institutions, communities, and local governments have been more or less successful at mitigating social isolation and loneliness among older adults?
    • Research considering how mitigation strategies and accompanying financial strain influence health care utilization and health, including individuals with disabilities, multiple chronic conditions, mild cognitive impairment, and/or Alzheimer’s disease and Alzheimer’s disease-related dementias, as well as their care partners and families. What are the interrelated health and economic implications of stay-at-home policies on the health and well-being of midlife and older adults with family care responsibilities, including care for children and older family members?
    • Evaluation of strategies used by health systems to reallocate resources, rapidly train practitioners, communicate preventative practices, and maintain adherence to public health and clinical guidelines during the COVID-19 pandemic, with a particular interest in those that serve high-risk groups (e.g., nursing homes) and resulting racial, ethnic, and/or regional disparities in access/care.
    • Studies examining the extent to which existing age, racial, ethnic, gender, socioeconomic, or geographic health disparities are exacerbated by the COVID-19 epidemic, including studies of 1) differential access to and use of health care services, and 2) differential access to information about, attitudes toward, and uptake of preventive measures, testing, and vaccines.
    • Research to address vaccine hesitancy, uptake, and implementation among NIH-designated health disparities populations and other COVID-19 vulnerable populations. For example: How do multilevel factors, including policies, health systems, communication modalities (e.g. social media), community-level factors, and interpersonal and individual-level variables reduce or maximize vaccine access, uptake, and series completion in different populations? How might programs to reduce concerns, increase trust and preparedness, and facilitate uptake of the vaccine be best implemented in various settings and environments (e.g., nursing homes, assisted living facilities, medical centers, dental clinics, community health clinics, pharmacies, Tribal health facilities, workplaces, pharmacies, remote care settings, and non-healthcare contexts)?

Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection (NOT-DA-21-011)

First Available Due date is June 5, 2021; Expiration Date is September 8, 2024.

  • The purpose of this notice is to communicate NIDA’s interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. This Notice is a reissuance of NOT-DA-20-084.
  • Research Objectives: NIDA is interested in receiving research applications focusing on individuals who smoke or vape either marijuana and/or tobacco to determine: 1) the risk of contracting a COVID-19 infection, 2) the effects on asymptomatic COVID-19 infected persons, and 3) the course of the COVID-19 infection.
  • This NOSI encourages research to understand:
    • The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.
    • The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.

The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.

Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases (NOT-AR-21-012)

Expiration date is November 19, 2021

  • The outbreak of COVID-19 caused by the novel SARS-CoV-2 has spread worldwide leading to large numbers of infections and deaths. A wide spectrum of clinical manifestations and outcomes, ranging from asymptomatic disease to multiorgan failure, has become a hallmark of the COVID-19 pandemic. Patients with many underlying diseases and conditions are at increased risk of acquiring and having adverse outcomes from SARS-CoV-2 infection. Furthermore, persistent symptoms (post-acute sequelae), including fatigue, muscle pain, weakness or wasting, joint pain, skin rash, arthritis, and biobehavioral changes, are being reported among COVID-19 survivors, even among individuals who initially experience a mild acute illness. As of this writing, the FDA has issued Emergency Use Authorization for two vaccines recommended to prevent COVID-19, and several other vaccines and treatments are in various stages of preclinical and clinical development. While there is no obvious indication of adverse events or impacts of the use of these vaccines in individuals with underlying rheumatic, skin, and or musculoskeletal diseases/conditions, research studies should be carried out to determine if these individuals will be affected differently by COVID-19 vaccines and treatments as compared to those without such conditions. In line with overall NIH efforts, NIAMS would like to promote basic, translational, pre-clinical and clinical observational research focused on COVID-19 infection and its intersection with rheumatic, musculoskeletal, and skin diseases and conditions.
  • This NOSI encourages, but is not limited to, research applications focused on:
  • Susceptibility to, prevalence, risk assessment, and clinical management of COVID-19 among patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
  • The impacts of drugs or other targeted therapies that are used to treat diseases within the mission of NIAMS on susceptibility, severity, and management of COVID-19;
  • Health disparities and social/behavioral factors that contribute to risk of infection, organ injury and adverse outcomes in COVID-19 patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
  • Impact of COVID-19 vaccination of patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
  • Characterization of long-term post-acute sequelae occurring in recovered COVID-19 patients with co-existing rheumatic, musculoskeletal, and/or skin diseases;
  • Characterization of NIAMS-mission related long-term post-acute sequelae (e.g. muscle pain, joint pain, biobehavioral changes, skin rash, arthritis, etc.) occurring in recovered COVID-19 patients.

Notice of Special Interest: Effects of smoking and vaping on the risk and outcome of COVID-19 infection (NOT-DA-20-084)

Expiration date is September 8, 2024; First Available Due Date is January 4, 2021

  • The purpose of this notice is to communicate NIDA’s interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.
  • Research Objectives: NIDA is interested in receiving research applications focusing on individuals who smoke or vape either marijuana and/or tobacco to determine: 1) the risk of contracting a COVID-19 infection, 2) the effects on asymptomatic COVID-19 infected persons, and 3) the course of the COVID-19 infection.
  • This NOSI encourages research to understand:
    • The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.               
    • The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
    • The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.

Notice of Special Interest: Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-21-006)

Expiration Date is March 17, 2021; First Available Due Date is October 30, 2020

  • National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.
  • The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include the following:
    • Testing a publicly posted therapeutic candidate for use to treat COVID-19. Examples include clinical candidate therapeutics in documents publicly posted by the World Health Organization (types/classes of candidate therapeutics) and (candidates for clinical evaluation).
    • Testing a candidate therapy to treat COVID-19 that was already identified with a publicly available computational approach.
    • Testing of existing therapeutic candidates that work on mechanistic targets shared among other viruses that may be relevant to SARS-CoV-2.

NCATS is soliciting applications to PAR-17-465, PAR-18-462, and PAR-18-332.

Notice of Special Interest: Research on Rehabilitation Needs Associated with the COVID-19 Pandemic (NOT-HD-20-031)

Expiration date is May 8, 2023; First Available Due Date: February 05, 2021

  • This NOSI invites research applications on the rehabilitation needs of COVID-19 survivors. At present, the best acute rehabilitation plan for people who have recovered from severe cases of COVID- 19 is unknown. Similarly, the long-term rehabilitation needs and sequalae of people who recover from COVID-19 are not well understood. Furthermore, the interplay of existing physical disabilities and recovery from COVID-19 is also unknown.
  • Research applications are also sought to understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions. Applications that measure the impact of delayed treatment for common disabling conditions, such as stroke, are also sought.
  • Finally, research applications investigating the social, behavioral, and economic impact of COVID-19 on people with physical disabilities and their caregivers are requested.
  • Topics of interest include but are not limited to:
    • New clinical trials of acute, chronic, home, and community-based rehabilitation interventions (types, dosing, timing, and intensity) for survivors of severe COVID-19 (e.g. with lung involvement, neurological symptoms, or muscle wasting)
    • EHR analysis of rehabilitation services associated with COVID-19 treatment
    • Physical, social, economic, and health outcomes for patients who receive COVID-19 rehabilitation
    • Studies of how pandemic containment and mitigation actions, such as social distancing requirements, affect the care and well-being of people with disabilities and their caregivers
    • Studies focused on addressing the unique needs of formal and informal caregivers in assisting/supporting survivors of COVID-19 use new methods of rehabilitation delivery during the pandemic
    • Studies of how social distancing guidelines and requirements are implemented and impact people with disabilities in institutions, group settings, and other non-traditional settings
    • Studies examining the impact of healthcare-related stigma, discrimination, harassment, and/or refusal of care on seeking COVID-related healthcare for people with disabilities
    • Development and testing of new methods for delivery of rehabilitation in the home. Target patient groups include both people requiring rehabilitation following COVID-19 as well as typical rehabilitation patients
    • Development and testing of novel metrics of function for use in the home environment with emphasis on the use of mobile or digital devices

Health Services Research on Minority Health and Health Disparities (R01 – Clinical Trial Optional) PAR-20-310

Application Due Dates: November 27, 2020; March 17, 2021; November 17, 2021; March 17, 2022; November 17 2022; February 17, 2023. Expiration Date is March 28, 2023.

  • The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.
  • Examples of research methods could include, but are not limited to:
    • Cluster-randomized, randomized or practical clinical trials of the effectiveness of new or existing technologies (e.g., telehealth), non-technological interventions, and multi-level interventions that involve broad inclusion of patients from health disparity populations and addresses a disease or condition that disproportionately impacts health disparity populations (e.g., infectious diseases such as COVID-19, chronic diseases such as cancer, diabetes, cardiovascular conditions, asthma, and others, mental health/substance abuse disorders including perinatal depression, and maternal and infant mortality).
  • Research topics of interest include but are not limited to:
    • Studies on the effects of emerging infectious diseases such as the COVID-19 pandemic on disparities in health care utilization and health outcomes among medically vulnerable populations such as institutionalized and non-institutionalized older adults; persons with chronic conditions, mental health and/or substance abuse disorders, complex medical needs, and/or with compromised immune system function; and pregnant women. In addition, examine the effects of these infectious diseases on disparities in health care utilization and health outcomes among socially vulnerable populations such as the homeless, the recently incarcerated, immigrants, persons with disabilities, and children.
    • Studies on the effects of the COVID-19 pandemic on disparities in access to care and quality of care for health disparity populations, taking into account how it impacts the structure and organization of different health care systems that serve health disparity populations, including those living in rural areas.
    • Research to examine the role of federal, state and local policies in different sectors (e.g., health care, labor, transportation, housing) in exacerbating or reducing the impact of the COVID-19 pandemic, chronic medical conditions, or other diseases that have disproportionate effects on minority health and health disparities.
    • Studies of clinical procedures or guidelines into existing care systems such clinician or health care system decision-making about advanced ventilatory support for patients with severe advanced COVID-19 or other acute severe diseases with high mortality.

Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract (NOT-HD-20-021)
Expiration date is 07/16/2023; First Available due date is 10/05/2020.

  • The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.
  • Currently, knowledge gaps exist in our understanding of viral infections of both male and female reproductive tract tissues. This NOSI is interested in the recently emergent ZIKA and novel corona viruses, as well as other yet unidentified viruses which may significantly impact public health. Areas of interest of this NOSI include, but are not limited to:
    • Consequences of infection, e.g., cells affected and outcomes of infection – infertility, miscarriage, live births, orchitis, epididymitis, pelvic pain;
    • Mechanism of action for infectivity of reproductive tract tissues;
    • Mechanism of sexual transmission;
    • Whether the reproductive tract acts as a reservoir for viruses;
    • Sex-specific differences in infection as they may relate to reproductive tract tissues and cells;
    • The impact of race and ethnicity on reproductive system impacts of viruses;
    • Impact of nutrition, e.g., Vitamin D sufficiency and the understanding of mechanisms that explain the impact of obesity;
    • Development of model systems to study infections in reproductive tract tissues, e.g., organoids (for R21 applications only)
  • Non-responsive applications:
    • Infections exclusively localized to the reproductive tract, e.g., urinary tract infections, chlamydia, HPV, HSV, hepatitis B;
    • Epidemiological analysis of a particular infection.

Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2
Expiration date is 9/1/2021; First Available due date is 9/01/2020

  • This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:
    • SARS-CoV-2 candidate vaccines
    • non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
    • therapeutic approaches to treat COVID-19
  • Please note, studies evaluating behavioral interventions (e.g., impact of face masks, hand- washing, social distancing) and those focused on disinfecting surfaces and equipment are not responsive and will not be considered for this NOSI initiative.
  • Investigators interested in responding to this NOSI are strongly encouraged to submit a written request for prior consultation to the email address listed below prior to submission of an NIAID Clinical Trial Implementation (U01) Cooperative Agreement application in response to PAR-18-633 to discuss the proposed project in the context of the needs identified above. This request should be as succinct as possible and include the study title and a brief description of the study and product to be evaluated; study PI; primary institution and potential collaborating sites; industry partners, if applicable; and a cost estimate. As a reminder, per NIH policy, applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact NIAID staff listed below no later than 6 weeks before submission and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) (PAR-20-238)
Application due dates: May 17, 2021, May 17, 2022, May 17, 2023

  • The purpose of this funding opportunity announcement (FOA) is to support research on interventions to improve health in Native American (NA) populations. This includes 1) etiologic research, where there is a significant gap in knowledge, that will directly inform intervention development or adaptations, 2) research that develops, adapts, or tests the efficacy or effectiveness of health promotion and disease prevention interventions, 3) research that tests culturally informed treatment or recovery interventions and 4) where a sufficient body of knowledge on intervention efficacy exists, research on dissemination and implementation that develops and tests strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions. Existing data suggest that significant acute and chronic disease inequities exist for NA populations.  Concurrently, NA populations experience unique sociopolitical, historical, and environmental stressors and risks that may exacerbate health conditions and/or impact the effectiveness of existing solutions to address the conditions. They also possess unique strengths and resiliencies that can mitigate stressors or inform intervention strategies. Through this initiative, intervention and related research is sought to build upon community knowledge, resources, and resilience to test science-based, culturally appropriate solutions to reduce morbidity and mortality through identification and remediation of precursors to diseases and disorders and through culturally informed treatment.  Interventions should be designed with a consideration for sustainability within the communities where they are tested, and have the flexibility to be readily adapted, disseminated, and scaled up to other communities where culturally appropriate. For the purposes of this FOA, Native Americans include the following populations: Alaska Natives, American Indians (whose ancestral lands fall at least partially within the U.S. mainland border), and Native Hawaiians.  The term ‘Native Hawaiian’ means any individual any of whose ancestors were natives, prior to 1778, of the area which now comprises the State of Hawaii.
  • NHLBI: One of the Examples of projects of interest to NHLBI include the following: Strategies and behavioral interventions that may mitigate the impact of COVID-19 on heart, lung, blood, and sleep diseases and disorders

Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations (NOT-MD-20-026)
First Available Due date 10/5/20; Notice expires on 5/8/21

  • The purpose of this Notice of Special Interest is to support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations.
    • One example of potential topic areas mentions COVID-19
      • Studies on the multi-level effects of the COVID-19 pandemic and/or their intersection on access to health care services and continuity of care, for example patient level factors (e.g., loss of health insurance due to job loss; impact on self-management due to caregiving and homeschooling responsibilities) health care setting level factors (e.g., changes and rescheduling of services due to policies on physical distancing; medication availability and refills, health care settings strategies and best practices to ensure appropriate and timely care), and societal factors (impact of policies on physical distancing on nutrition, physical activity, and emotional well-being). Costs/economic analyses are of interest.

Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01)
Applications will be accepted on a rolling basis, beginning on 8/6/2020

  • The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

Notice of Intent to Publish a Funding Opportunity Announcement for HEALthy Brain and Child Development Study (NOT-DA-20-069)

  • NIH plans to publish a set of Funding Opportunity Announcements (FOAs) as part of the Helping to End Addiction Long-termSM (HEAL) Initiative to support research project sites, a Data Coordinating Center, and a Consortium Administrative Core for the HEALthy Brain and Child Development (HBCD) Study. The primary objective of the HBCD Project is to conduct a large scale multi-site longitudinal study that can prospectively examine human brain, cognitive, behavioral, social, and emotional development beginning at birth and extending through middle childhood. The FOAs are expected to be published in Fall 2020 with an expected application due date in WINTER 2021.

Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders
This notice applies to standard R01 and R21 due dates on or after October 5, 2020 and subsequent due dates until 1/8/24.

  • We expect this NOSI to accelerate the development of 1) remotely-delivered SUD treatment interventions, and 2) remote methods for collecting outcome measures evaluating the safety or efficacy of SUD treatments. These advances will facilitate the delivery of effective treatments to those in need and permit the execution of clinical trials when physical access to clinical research sites is limited. Ultimately, both these advances will lead to improved treatment options for individuals with SUD.

Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders
This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2022.

  • NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

RadX – Tech – NIH POCTRN Fast-Track Program for COVID-19 Test Development and Distribution Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing
Accepting proposals for support on a rolling basis until further notice

  • NIBIB is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities.

Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) (PA-20-172)
Standard due dates starting 10/5/20

  • This FOA supports investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters, such as the COVID-19 pandemic, on health care systems serving health disparity populations in communities in the U.S.

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) (RFA-ES-19-011 / NOT-ES-20-015)
Applications are accepted the first week of each month. See Notice for specific dates. (Notice expires on 5/4/21)

  • NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. NIEHS is accepting applications addressing COVID-19 through the urgent competitive revision, and time-sensitive mechanisms (see Application Information below).

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-007)
Application standard due dates apply (Notice expires on 3/31/21)

  • The NIBIB is seeking new R01, R21, and R03 applications to develop life-saving technologies that can be ready for commercialization within one to two years.

Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-006)
Standard application due dates apply (Notice expires on 3/31/21)

NIAID Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-031)
Application due dates depend on grant mechanism (Notice expires on 4/5/21)

  • National Institute of Allergy and Infectious Diseases (NIAID) is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. Applications may be submitted through R03, R21, or R01 mechanisms.

NSF Funding Opportunities & Priorities

Trans-Atlantic Platform Recovery, Renewal, and Resilience in a Post-Pandemic World (PD-21-188Y)

Current Closing Date for applications is July 12, 2021

  • The Trans-Atlantic Platform Recovery, Renewal, and Resilience in a Post-Pandemic World (T-AP RRR) opportunity supports international, collaborative research projects that address key gaps in our understanding of the complex societal effects of COVID-19. Specifically, T-AP RRR supports research that addresses one or more of the following challenges: reducing inequalities and vulnerabilities; building a more resilient, inclusive, and sustainable society; fostering democratic governance and participation; advancing responsible and inclusive digital innovation; and/or ensuring effective and accurate communication and media.
  • Proposals requesting NSF funding must fit within the scientific purview of the NSF Directorate for Social, Behavioral and Economic Sciences (SBE). Proposers are strongly encouraged to consult SBE’s programs and contact the cognizant program director (see Contacts, above) to discuss their proposals’ fit within NSF/SBE’s purview prior to submission of the international team proposal to the T-AP RRR Call.
  • T-AP RRR supports collaborative research teams from four continents: Africa (Republic of South Africa); Europe (Croatia, Finland, France, Germany, Poland, Switzerland, and the United Kingdom); North America (Canada, the United States); and South America (Brazil and Colombia). Teams must include researchers based in at least three participating T-AP RRR countries and must include partners from both sides of the Atlantic, i.e., from Europe/Africa and the Americas. Research partners will receive funding from their own national funding agencies for projects of up to 36 months in duration.

Joint NSF-BSF Programs Dealing with the Coronavirus Disease
Applications may be submitted anytime

  • The U.S.-Israel Binational Science Foundation (BSF) is accepting applications dealing with the Coronavirus Disease in all the active NSF-BSF programs. Applications must be written jointly by an Israeli scientist in an Israeli institution and a U.S. scientist from a U.S. research institution. Proposals should be submitted through the NSF Rapid Response Research (RAPID) funding mechanism. Presently, all biology units of the NSF (BIO), Geosciences, Materials, Physics and CBET divisions are open for submission.

NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) (NSF 20-052)
Applications may be submitted anytime

  • NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

Centers for Disease Control and Prevention

None currently posted.

Department of Energy/Private Sector

COVID-19 High Performance Computing (HPC) Consortium Request for Proposals
Applications may be submitted anytime

  • The COVID-19 High Performance Computing Consortium is a unique private-public effort to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines. Researchers are invited to submit COVID-19 related research proposals to the consortium, which will then be reviewed for matching with computing resources from one of the partner institutions.

Department of State

2020 TIP Office Annual Program Statement to Address the Impacts of COVID-19 (SFOP0007233)

  • This announcement is specifically focused on addressing short-term, targeted needs related to COVID-19 and human trafficking. The Department of State is rising daily to meet the historic challenge posed by the COVID-19 pandemic, all over the world. Despite the COVID-19 pandemic, traffickers continue to operate to ensure victims are not free to choose where they live, how they work, or who has access to their bodies. Economic uncertainty, movement restrictions, lockdowns, and disruptions to state services have made the most vulnerable more vulnerable. Traffickers are capitalizing on the chaos of the pandemic, finding ways to increase their exploitation. As government and philanthropic efforts and resources are stretched to respond to the pandemic, financial support for anti-trafficking efforts is limited. The TIP Office recognizes the impact COVID-19 has on efforts to combat human trafficking, and seeks to address the specific short-term challenges that have arisen from the pandemic.
  • The Department of State’s Office to Monitor and Combat Trafficking in Persons (TIP Office) announces an open competition for funding to address the impacts of COVID-19 on efforts to combat human trafficking and support government measures to counter human trafficking outside the United States.
  • The Annual Program Statement is an open-ended, annual funding opportunity to generate competition for new awards. The Annual Program Statement is open for approximately one year (August 14 – June 30, 2021), during which U.S.-based and foreign non-profits, non-governmental organizations (including faith-based organizations), public international organizations, institutes of higher education, and for-profit entities can submit applications at any time. The TIP Office will allocate up to $3.5 million for this initiative and plans to issue awards on a regular basis to address the rapidly changing needs and opportunities. Applicants may submit applications for no less than $100,000 to work in one or more countries that directly aligns with the programming priorities listed in this announcement. This announcement is specifically focused on projects that address short-term targeted needs related to COVID-19 and human trafficking.

Counter misinformation and disinformation about COVID-19 in Malawi
Deadline for applications is March 23, 2021

  • The Government of Malawi announced its intention to roll out COVID-19 vaccine distributions to the populace in March.  However, some Malawians are spreading misinformation among the populace, leading to building mistrust and suspicion of the vaccine’s safety, in both rural and urban areas.  This misinformation is being spread on popular social media platforms, and word of mouth.   The objective of the grant would be to spread more positive messages about COVID-19 vaccination at a grassroots, non-governmental level in Malawian communities. Length of performance period is 3 to 6 months; number of awards anticipated is 1; Award of up to $50,000. Note: Only projects that take place in Malawi will be considered. PAS encourages applicants to provide cost-sharing from additional sources in support of the proposed project.
  • This call is for proposals for innovative projects that (Please note: Application that do not specifically address one of the four topics will be disqualified):
    • Counter misinformation and disinformation about the COVID-19 vaccine, including, but not limited to, information campaigns, social media campaigns, training for journalists about the science behind vaccines, educational activities for students, etc.
    • Teach communities where COVID-19 vaccine skepticism is observed, to think critically about information they see on social media about the COVID-19 pandemic and vaccine, including examining sources, evaluating multiple points of view, and considering the agendas of information sources.
    • Equip educators to teach students in rural and underserved areas to think critically about information they see on social media about the COVID-19 pandemic and vaccine, including examining sources, evaluating multiple points of view, and considering the agendas of information sources.
    • Achieve an increase in the number of  Malawians, those who previously expressed suspicion and even rejection of COVID-19 vaccines, reporting a change of attitude and now positive reception to the idea of being vaccinated. 
    • Achieve an increase in the number of Malawians receiving the vaccine, in areas where vaccine skepticism was earlier observed. 

Environmental Protection Agency

EPA Environmental Justice Collaborative Problem-Solving (EJCPS) Cooperative Agreement Program (PLEASE NOTE: Colleges and Universities are INELIGIBLE to receive an award but the EPA encourages other organizations to partner with colleges and universities, as appropriate).  (EPA-OP-OEJ-21-02)

Deadline for submission is May 7, 2021

  • The total estimated funding for this competitive opportunity is approximately $3,200,000. EPA anticipates awarding a total of twenty cooperative agreements of approximately $160,000 each within the 10 EPA Regions, subject to availability of funds, the quality of applications received, and other applicable considerations. Funded assistance agreements will have a two-year project period. Applicants should plan for projects to start October 1, 2021.
  • A key starting point for any collaborative problem-solving project is the identification of an environmental and/or public health issue and the community’s leadership in formulating goals (e.g., diesel reduction, lead abatement, reducing high incidence of asthma, land use changes, pollution prevention, implementation of fish advisories, hazardous waste, emissions reduction, risk reduction, community cleanups, or compliance with local environmental and/or public health regulations, etc.). Collaborative problem-solving involves the establishment and/or maintenance of partnerships between and among other stakeholders and the underserved community to address the community’s local environmental and/or public health issues.
  • For this competition, EPA may give special consideration to high ranking applications that focus on the following program priorities:
  • Public Education, Training, Emergency Planning, and/or Investigations on Impacts of COVID-19 on Underserved Communities and Vulnerable Populations– EPA may give special consideration to projects that address the impacts that the current COVID-19 pandemic has on vulnerable populations. Applicants may use funding to conduct public education, training, outreach, investigations and/or develop plans and programs to specifically work on mitigating the impacts of COVID-19 on EJ communities. Applicants are encouraged to develop innovative plans and processes to conduct effective outreach to underserved communities in the midst of social-distancing and local stay-at-home orders, especially in places where internet access may not be readily available to all residents. To qualify for this special consideration, applications must address the impacts of COVID-19 through eligible activities (see Section I.) Examples of eligible activities include (but are not limited to) 1) sharing information related to EPA-approved disinfectants to combat COVID-19 (List N: Disinfectants for Use Against SARS-CoV-2), 2) addressing underserved residents’ increased exposure to in-home pollutants and healthy housing issues as an unintended consequence of local stay-at-home orders, and 3) training of community health workers as community educators for environmental justice communities. NOTE: EJSG funds cannot be used for Human Health Studies, including taking blood or other medical information from humans.
  • Projects addressing Climate, Disaster Resiliency, and/or Emergency Preparedness – The effects of climate change and extreme weather events tend to adversely impact the most vulnerable communities and populations disproportionately. Therefore, EPA may give special consideration to projects that address the needs of underserved and vulnerable communities that have been adversely impacted or are likely to be adversely impacted by natural disasters, including, but not limited to, hurricanes, tornadoes, wildfires, floods, earthquakes, and future pandemics.
  • New applicants and grantees – High ranking applicants who have never received an EPA EJCPS award may receive additional consideration during the selection process in order to broaden the universe of EJCPS grantees.

Environmental Justice Small Grants Program (PLEASE NOTE: Colleges and Universities are INELIGIBLE to receive an award but the EPA encourages other organizations to partner with colleges and universities, as appropriate).  (EPA-OP-OEJ-21-01)

Deadline is May 7, 2021

  • The Environmental Justice Small Grants (EJSG) Program provides funding directly to eligible applicants for projects that help residents of underserved communities understand and address  local environmental and public health issues. For purposes of this announcement, the term “underserved community” refers to a community with environmental justice concerns and/or vulnerable populations, including people of color, low income, rural, tribal, indigenous, and homeless populations that may be disproportionately impacted by environmental harms and risks. In general, the EJSG program awards grants that support community-driven projects designed to engage, educate, and empower communities to better understand and address local environmental and public health issues. Community-driven projects are projects that include activities where community residents and/or representatives are integrally involved in the thinking behind and execution of those activities. Therefore, applying organizations should have a direct connection to the underserved community impacted by environmental harms and risks.

NASA

Making Innovative Use of NASA Satellite Data to Address Environmental, Economic, and/or Societal Impacts of the COVID-19 pandemic
Applications will be accepted on a rolling basis through 3/29/21

  • NASA’s Earth Science Division (ESD) would like to call the attention of the Earth Science research, applications, and data systems communities to Program Element A.28 “Rapid Response and Novel Research in Earth Science” (RRNES) of Research Opportunities in Space and Earth Sciences (ROSES) 2020 as an opportunity to propose investigations making innovative use of NASA satellite data to address regional-to-global environmental, economic, and/or societal impacts of the COVID-19 pandemic.

NIST

NIST Manufacturing USA National Emergency Assistance Program (2020-NIST-MFGUSA-NEAP-01)
Applications will be accepted on rolling basis
(Washington University is not eligible as the lead institution but may participate on an application.)

  • National Institute of Standards and Technology (NIST) invites Manufacturing USA institutes to propose high-impact projects designed to respond to the COVID-19 pandemic.  Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.

USAID

COVID-19 FUNDING REQUESTS AND UNSOLICITED PROPOSALS
Concepts accepted on a rolling basis

  • USAID is responding to the COVID-19 pandemic with decisive action at home and abroad. Our priorities in the COVID-19 response are to protect the safety and health security of our global workforce, ensure that we can continue our life-saving mission across the world, and support partner countries in their response to COVID-19. Partners may submit unsolicited proposals to COVID19_Concepts@usaid.gov.

Non-Federal Opportunities

*NEW*Engagement Award Special Cycle: Building Capacity for PCOR/CER for Topics Related to COVID-19

Full Proposals are due May 24, 2021 (5 PM ET)

  • This Eugene Washington PCORI Engagement Awards Special Cycle Funding Announcement—Building Capacity for PCOR/CER for Topics Related to COVID-19 is a research support – not research—special funding opportunity for projects up to 18 months in duration and up to $200,000 in total costs. The length of the project period and budget amount must be justified by the level of activity that will occur during the project and all projects must be at least 12 months in duration.
  • This special funding opportunity will support projects that enable organizations and communities to build their capacity and skills to participate across all phases of the PCOR/CER process on topics that address health outcomes related to COVID-19. Projects will also provide an understanding of the impact of stakeholder engagement strategies within different settings and stakeholder groups focused on this special area of interest.
  • In the context of the Engagement Awards program, capacity building to support research refers to the following types of projects:
    • Projects that focus on building the knowledge, competencies, and abilities of patients and other stakeholders to be meaningful partners in PCOR/CER with researchers throughout the research process, from topic selection through design and conduct of research to dissemination or implementation of results.
    • Projects that strengthen the skills of researchers to be better partners with patients and other stakeholders involved in PCOR/CER.
    • Projects that support the expansion of use or adoption of existing engagement tools and resources to build capacity for PCOR/CER in a new population or geographic area.
  • This is an opportunity to explore and address the urgent and unique needs to build capacity for stakeholder engagement in PCOR/CER specifically related to:
    • Long-term effects of post-acute COVID-19;
    • Impact of COVID-19 on disproportionately affected populations;
    • Impact of COVID-19 on social isolation and loneliness (mental health and well-being); and
    • Engaging, educating, and promoting informed decision making around COVID-19 vaccines.
  • Other relevant topics related to COVID-19 health outcomes with appropriate justification will also be considered.

National Geographic Society COVID-19 Science Fund

Statement of interest will be accepted through 11:59 PM EDT March 31, 2021.

  • In response to worldwide disruptions from the COVID-19 pandemic, the National Geographic Society is providing funding for projects focused on how humanity and the natural world have reacted to and are living through the unparalleled circumstances created by COVID-19 in order to better understand how this pandemic—or the threat of another—will shape our world for years to come. Proposed projects should seek to better understand and/or provide solutions to the situations created or magnified by the pandemic, thereby helping us to understand and address the challenges and changes of living in a COVID-19 world. This fund invites research, conservation, and technology projects on the following two (2) topics; below are examples of the types of questions and projects that the Society would like to receive:
  • Community-based and inclusive conservation.
    • How have community and grassroots organizations been impacted by COVID-19?
    • How have organizations continued their conservation activities during the pandemic? What types of new models or innovative approaches to conservation are being tried?
    • How are local communities that have depended on external visitors or revenues for their livelihoods and other conservation activities, adapting to the new context?
    • With people unable to afford to stay in cities, how are rural communities shaped and changed by people returning?
    • Given the ongoing economic crises due to COVID-19, what lessons can be applied post pandemic to support sustainable and just economic recovery in areas with high biodiversity and/or cultural heritage resources?
  • Impacts of tourism changes on cultural heritage sites and wildlife.
    • How have changes in global and/or domestic tourism affected wildlife, protected area management, cultural heritage site conservation, and the livelihoods and well-being of nearby communities?
    • What lessons can be applied for when/if tourism returns?
    • How has tourism been re-invented during the pandemic? What types of new models or innovative approaches to tourism are being tried?
    • Some natural and cultural heritage areas may have seen increased domestic and local tourism as a result of the pandemic – what are the impacts, if any?
  • Only applications that propose activity in the applicant’s country of residence will be considered. Budgets: Funding requests of up to $50,000 will be accepted for review. Applicants will receive decisions on their statement of interest by April 8, 2021. Full applications will be due by 11:59pm EDT May 19, 2021. Applicants will receive a funding decision in summer 2021. Proposed project activities should occur after funding decisions are made.

Longer Life Foundation Call for Applications: Developmental Research Awards – Letters of Intent are due by Midnight of February 19, 2021. Call for Applications  

  • An interactive session with Dr. Dominic Reeds, Director of the Longer Life Center, and Dr. Dan Zimmerman, Managing Director of the Longer Life Foundation, will be held on Wednesday, January 27, 2021 from 9:00 – 10:00 AM via Zoom.  Registration is required (register here). This Q&A session is offered to provide feedback on potential ideas for award applications, as well as technical details about the grant application and review processes.
  • The Longer Life Foundation’s mission is to fund and support the study of factors that either predict the mortality and morbidity of selected populations or influence improvements in longevity, health, and wellness.
  • These grants are specifically for either junior investigators who are interested in longevity-related research and have yet to obtain independent funding, or for established investigators who are developing a new direction in research on determinants of health and longevity. These awards provide up to $50,000 direct costs per year for up to 2 years to support these missions. Further, hands-on mentorship to assist scientific development is provided to junior faculty who are beginning their research careers. These grants have proven highly effective at generating pilot data for junior investigators and in allowing them to successfully compete for funding from national agencies. Please note: in the updated RFP, the project ideas have been expanded to include a few COVID-related topics.
    • Pandemic risk modeling and ways of mitigating catastrophic outcomes
    • Long-term impact of COVID-19 on mortality and morbidity outcomes

Wellcome, Bill & Melinda Gates Foundation, and Mastercard
The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.

Topics: The Accelerator is seeking partners for the following activities:

  • Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
  • Developing drugs or monoclonal antibodies that pass initial screening.
  • Scaling up production and commercialization of successful drugs and monoclonal antibodies.

CISCO Pandemic/COVID19 Science, Technology and Social Impact

  • Cisco is interested in both the science and technology aspects of these problem sets, and, particularly, in the intersections between them. By cultivating stronger partnerships between scientists, technologists, and the broader community; we hope to achieve an acceleration of scientific research and conservation outcomes as we push the boundaries of our technologies and architectures to support larger-scale studies, more sophisticated analyses, and translation of learnings across multiple domain areas.

COVID-19 Early Treatment Fund (CETF)
Applications are accepted on a rolling basis

  • CETF is raising funds to test the most promising existing drugs in outpatient trials and helping those studies recruit patients. We are the only organization in the world that is exclusively focused on outpatient trials testing treatments immediately after infection. A scientist can apply for funding and get up to a $1M commitment in less than a week. Funding multiple shots on goal quickly is the fastest way to end the pandemic.

Robert Wood Johnson Foundation (RWJF): Pioneering Ideas – Exploring the Future to Build a Culture of Health
Proposals will be accepted on a rolling basis throughout the year

  • Pioneering Ideas: Exploring the Future to Build a Culture of Health seeks proposals that are primed to influence health equity in the future. The Foundation is interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. RWJF welcomes proposals from scientists, anthropologists, artists, urban planners, and community leaders – anyone, anywhere who has a cutting edge idea that could alter the trajectory of health and increase opportunities for everyone in the United States to live their healthiest life possible.
  • While this RFP is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, the Foundation recognizes the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.

Mozilla Open Source Support Program (MOSS) COVID-19 Solutions Fund
Applications are accepted on a rolling basis

  • Mozilla will provide awards of up to $50,000 each to open source technology projects which are responding to the COVID-19 pandemic in some way. As part of the COVID-19 Solutions Fund, we will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation).

FastGrants – Fast Funding for COVID-19 Science
Applications accepted on a rolling basis – current on hold due to large number of application received.

  • Science funding mechanisms are too slow in normal times and may be much too slow during the COVID-19 pandemic. Fast Grants are an effort to correct this. If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. If we approve the grant, you’ll receive payment as quickly as your university can receive it

PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Research
Applications accepted on a rolling basis

  • PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis through enhancements of currently funded PCORI research awards. Only PCORI-funded principal investigators with active research project funding contracts are eligible to submit a proposal in response to this announcement.

Wellcome Trust – Epidemic Preparedness: COVID-19 Funding Call
Applications accepted on rolling basis

  • Applicants must be able to swiftly begin to investigate new approaches for preventing and controlling COVID-19. Proposals should focus on helping low- and middle-income countries prepare for and deal with the epidemic. Eligible applicants are researchers with a PhD or the equivalent, and significant postdoctoral research experience. These awards are open to individuals or teams of up to five members. Applicants can be based anywhere in the world (apart from mainland China). Wellcome Trust particularly encourages applications from lead applicants based in low- and middle-income countries.

Relevant Links

Additional COVID-19 Funding Opportunities

SPIN COVID-19 Links

Webinar: Proposal Writing in the Time of COVID-19 Recording and Slides from June 11, 2020.

COVID-19 & Social Determinants of Health Working Group

  • Lead by Karen Joynt Maddox, MD, MPH, co-director of the Center for Health Economics and Policy, the Institute for Public Health’s COVID-19 and Social Determinants of Health Working Group convenes regional researchers, practitioners and public health workers interested in discussing research, data, and opportunities for collaboration.
  • According to Dr. Joynt Maddox, the goals of the group are to “connect people across the university around this important topic to enable novel collaborations and help create meaningful change in clinical care and policy.”

Pew Charitable Trusts: Science Matters
April 16, 2021
11 a.m. – Noon (Central)
Register here

  • COVID-19 has created challenges that the world has not seen in more than a century and thrust science itself under the microscope. Vaccines, therapeutics, and epidemiology are now topics of conversation in the public square, and the need for researchers to effectively communicate about their work has never been more essential.
  • Join us for a discussion with expert contributors to Pew’s latest issue of Trend magazine on how scientists can build trust with the public and how the lessons from the pandemic can change the practice of science for the better. Read more at pewtrusts.org/trend.